EVENTS | VIEW CALENDAR
MSKCC selects Ascentos software for preclinical research
MT. ARLINGTON, N.J.—PDS Life Sciences, a leading global provider of intuitive data management software and solutions for life-sciences research, announced recently that Memorial Sloan Kettering Cancer Center (MSKCC) has opted to use PDS’ Ascentos software suite to manage and analyze data that will be generated in its new GLP-compliant preclinical research laboratories.
Ascentos software includes toxicology, clinical pathology, reproductive toxicology and pathology modules that are intended to streamline data management from study setup to final reporting. Ascentos is said by PDS to be “a complete FDA SEND-ready preclinical solution, because it captures data required by current and future versions of the CDISC SEND data standard.”
After a rigorous, competitive assessment, according to PDS, MSKCC selected Ascentos because of its intuitive processes, rapid implementation and ability to automate fundamental laboratory workflows.
“We develop software that works like scientists think,” said Sayed Badrawi, CEO of PDS. “As innovative companies and research institutions continue to choose PDS’ Ascentos over the alternatives, it’s become clear that building software for the user—not just the data being compiled—is a key driver of value in the market.”
For more than 30 years, PDS has provided intuitive data management software and solutions for life-sciences research and development programs worldwide, and the company says most of the world’s top 10 pharma companies rely on PDS software, as do industry-leading contract research organizations, chemical companies, universities and regulatory agencies. The PDS software lineup is centered on Ascentos, an integrated preclinical software solution that is purpose-built to support toxicology, clinical pathology, reproductive toxicology and anatomic pathology. PDS also offers TranSEND, a complete FDA SEND submission management solution, as well as bioinformatics analysis and other services.